Biologics License Application

FDA states that LN-145 in NSCLC is likely to receive accelerated approval

FDA states that LN-145 in NSCLC is likely to receive accelerated approval

SG Tylor

Source – Iovance Biotherapeutics The Phase II IOV-LUN-202 trial of LN-145 in patients with post-anti-PD-1 non-small cell lung cancer (NSCLC) ...

Moderna Submits Global Regulatory Applications for its RSV Vaccine, mRNA-1345 - USA Pharma News By Pharmtales

Moderna Submits Global Regulatory Applications for its RSV Vaccine, mRNA-1345

SG Tylor

Source – Moderna On July 5, 2023 Moderna, a biotech company at the forefront of mRNA vaccines, shared an update ...